Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure

On June 7, 2017, management of Immune Therapeutics, Inc., a
Florida corporation (the Company) gave a presentation related to
the business and performance of the Company at LD Micro 7th
Annual LD Micro Invitational Conference at the Luxe Sunset Bel
Air in Los Angeles.

Copies of the presentation slides presented at the conference are
attached hereto as Exhibit 99.1. The information contained herein
and the exhibit attached hereto shall be deemed furnished and not
filed. The information contained in the presentation slides has
been provided for information purposes only and should not be
construed as an offer to sell or a solicitation of an offer to
purchase any of the Companys securities.

Section 9 Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are filed herewith.

About Immune Therapeutics, Inc. (OTCMKTS:IMUN)

Immune Therapeutics, Inc. is a biotechnology company. The Company is involved in the manufacturing, distribution and marketing of therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy. The Company’s products and immunotherapy technologies are designed to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. Its technology platform is built on various immunotherapies, such as Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Its technology offers treatment for a range of cancers. The Company’s clinical programs involve immunotherapy with Methionine-Enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which stimulates the immune system even in patients with advanced cancer.